Navigation Links
Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
Date:10/5/2009

n arterial thrombosis applications, initially in Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention. REG2, Regado's second product candidate, consists of a subcutaneously administered formulation of RB006 paired with the IV bolus formulation of RB007. REG2 is intended for use in venous thrombosis indications

ABOUT APTAMERS

RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing it biologic effects.

More information can be found at http://www.regadobio.com

SOURCE Regado Biosciences, Inc.


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
2. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
3. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
4. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
5. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
6. Regado Biosciences Expands Medical Advisory Board
7. Regado Biosciences Establishes Medical Advisory Board
8. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
9. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
11. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
(Date:12/19/2014)... Dec. 19, 2014 Decision Resources Group finds ... at a 12 percent compound annual growth rate through ... aging population and the increasing adoption of dental implants. ... will also spur demand for dental biomaterials because ... and periodontal treatments. Other key findings from ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... Jan. 3 Escalon Medical Corp.,(Nasdaq Capital Market: ... 510(k) clearance from the U.S. Food and Drug,Administration ... The MASTER-VU(TM) System consists of a B-scan probe ... (via a USB cable,connection) using Sonomed,s proprietary software, ...
... Jan. 3 Cinpathogen, through its,partnership in the ... clinical diagnostic technology consulting,services to Shanghai area hospitals. ... the,Shanghai Health Study, the Center has diagnosed and ... in collaboration with area,hospitals and colleagues at Fudan ...
... KENILWORTH, N.J., Jan. 2 Schering-Plough,Corporation (NYSE: ... and Drug,Administration (FDA) has assigned priority review status ... Sugammadex is specifically designed to reverse the ... States as ZEMURON(R) (rocuronium,bromide) and vecuronium bromide. Muscle ...
Cached Biology Technology:Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System 2Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System 3Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 3Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 4
(Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "iPhone 5S Fingerprint ... Report" report to their offering. ... the acquisition of AuthenTec in July 2012, Apple ... 5S. It is currently the only device of ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first ... The Galaxy S5 home button presents an ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... New York University biologists have uncovered how the innate ... neurons. The findings, published as the cover study in ... neurons fight the virus at multiple stages--by preventing the ... virus' release, which could infect other cells in the ...
... today in the journal Genome,Research that they have ... a 554-kilobase-pair genomic,segment near the centromere of the ... genes that could be implicated in,sex-associated height differences ... one of the few holes remaining in the,"finished" ...
... in comparison to the 3.2 gigabases of its human ... 14 proteins, which play different roles in promoting viral ... host’s cellular machinery—including RNA polymerases, which carry out transcription—to ... chromosomal DNA. Once the virus is integrated (now called ...
Cached Biology News:NYU Study Reveals How Brain's Immune System Fights Viral Encephalitis 2Found: Missing sequence of the human Y chromosome 2Found: Missing sequence of the human Y chromosome 3Novel Enzyme Shows Potential As An Anti-HIV Target 2Novel Enzyme Shows Potential As An Anti-HIV Target 3